All News

Lungs breathing

RA-ILD takes centre stage

d Richard Conway, MBBChBAO, PhD

Interstitial lung disease is common in RA, occurring in approximately 8% of RA patients. It is associated with a poor prognosis, and a median survival of 3 years. This important condition has often been neglected within the spectrum of RA research. That is changing, with excellent research initiatives presented at ACR22. I am going to highlight two select abstracts from Monday’s dedicated RA-ILD session.

Read Article
Sleep asleep

Sleep Quality & Psoriatic Arthritis

d Olga Petryna, MD

For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.

Read Article
gout.MTP_.jpg

Methotrexate + pegloticase increases response rates in gout

d Bella Mehta, MBBS, MS

In abstract 0001 presented at ACR22 Convergence, researchers presented 12-month data from a randomized double-blind placebo-controlled trial of pegloticase with or without MTX.

Read Article
lupus SLE

Dual target blockade may be better than one in SLE

d Md Yuzaiful Md Yusof, MRCP(UK), PhD

Inhibition of B-cell Activating Factor (BAFF) has revolutionised the treatment of patients with systemic lupus erythematosus. However, outcomes of therapies within the same class (i.e. BAFF-inhibitor) when evaluated in randomised controlled trials have been inconsistent.

Read Article
Best of

ACR Best Abstracts - Day 3

d Jack Cush, MD

The last day was jammed with important reports and research including the late breaking abstracts. 



 

Read Article
tumeric

The spicy topic of turmeric in rheumatoid arthritis

d David Liew, FRACP

Curcumin, the active constituent of turmeric extract, has increasingly been promoted as a potential rheumatoid arthritis therapy, but data presented at ACR22 suggests that even in ideal situations, it is unable to do any better than placebo in replacing conventional RA therapies.

Read Article
“Hey PRESTO!” – Early identification of psoriatic arthritis The past decade has seen the management of psoriatic arthritis (PsA) transform, with our rich therapeutic armamentarium truly revolutionising patient outcomes. https://t.co/FJNX3mGCoy https://t.co/Whd8QKwmkU

Links:

Dr. John Cush RheumNow ( View Tweet)
Effect of voclosporin in class V lupus nephritis Dr. Yusof ( @Yuz6Yusof) discusses abstract 0355 presented at #ACR22. Abstract 0355: Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study https://t.co/v716QGx73g https://t.co/ANTOEDAAHt

Links:

Dr. John Cush RheumNow ( View Tweet)
The CONSUL Trial: Ankylosing Spondylitis Dr. Sheila Reyes ( @RHEUMarampa) discusses abstract 0546 presented at #ACR22. https://t.co/DXTn3XfEzC https://t.co/pbORtBsRm2

Links:

Dr. John Cush RheumNow ( View Tweet)
JAK vs TNF inhibitor Infections in RA Dr. David Liew ( @drdavidliew) discusses abstract 0302 at #ACR22 Convergence. Abstract 0302: Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis https://t.co/GsOsWtuT7v https://t.co/GloKEcB75L

Links:

Dr. John Cush RheumNow ( View Tweet)
Does BASDAI work for women? In Abstract 0406 S. Maguire et al sought to understand if BASDAI and BASFI captured disease activity and quality of life in female axSpA patients. Read more from Dr. Rachel Tate ( @uptoTate ) #ACR22 https://t.co/yWzdRMPgpp https://t.co/YrMsAYbAWN

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Best Abstracts - Day 3 The last day was jammed with important reports and research including the late breaking abstracts. These were some of our favorites. #ACR22 https://t.co/vUrxBTF3Wj https://t.co/QKpTjyFfxt

Links:

Dr. John Cush RheumNow ( View Tweet)
#ACR22 final plenary session 10 week study outcomes of Philly vs Placebo to be reported #rheumpix @RheumNow https://t.co/BradH2Ty70
Eric Dein ericdeinmd ( View Tweet)
Can you put a bit of morphine intraarticularly inside an osteoarthritic knee and make it better? Cute idea, no bingo. I get that we're chasing better symptomatic solutions, but... Don't do this. ABST1833 #ACR22 @RheumNow https://t.co/pvsGx93eoU
David Liew drdavidliew ( View Tweet)
Erosive OA: have we got anything disease-modifying? Not much right now (read: nothing) Denosumab 60mg q3mo for bone remodelling? radiographic change, erosive jt development: real improvement pain, function: zip at 48w, some at 96w? Def worth more study! ABSTL05 #ACR22 @RheumNow https://t.co/Yo9u5BlYYJ
David Liew drdavidliew ( View Tweet)
PAN relapse risk ⬆️ in: 👉severe GI involvement 🧓>65y/o 👉skin necrotic lesions PAN ⬆️ mortality wt: 👉AKI 🧓>65y/o 👉necrotic purpura 👉secondary PAN Abst#2232 @RheumNow #ACR22

Patricia Harkins DrTrishHarkins ( View Tweet)

Abstr #2196- COVID-19 outcomes in IMID dx in large US Hospital vs Pre-Omicron - ↑ COVID + rate (21.9% vs 7.9%) - ↓ hospitalized (0.8% vs 3%) & death (1.8% vs 4.5%) - Hospitalization & death > gen pop both pd. -Age & comorbidities assoc w worse outcomes @RheumNow #ACR22

Akhil Sood MD AkhilSoodMD ( View Tweet)

Biosimilar multi-switching in RA: is it an issue? Switching back & forth between originator & biosimilar should create ideal conditions for immunogenicity or anti-drug Ab This study: multi-switching vs no switching No issues at all Switch away in RA! ABST1589 #ACR22 @RheumNow https://t.co/pGBF2BHp7y
David Liew drdavidliew ( View Tweet)
We want to see how you are taking in #ACR22! Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/ygfYol5Z3f
Dr. John Cush RheumNow ( View Tweet)
ACR2022 Topic Panels https://t.co/5gMfFS8maR

Links:

Dr. John Cush RheumNow ( View Tweet)

×